Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

b. braun melsungen aktiengesellschaft (3049484) - ropivacainhydrochlorid-monohydrat - injektions-/infusionslösung - ropivacainhydrochlorid-monohydrat (24086) 2,116 milligramm

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

b. braun melsungen aktiengesellschaft (3049484) - lösungsmittel zur herstellung von parenteralia

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

b. braun melsungen ag - lösung

Union européenne - allemand - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Union européenne - allemand - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 und 5. 1 für verfügbare daten zu verschiedenen kombinationen).

Union européenne - allemand - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 und 5. 1 für verfügbare daten zu verschiedenen kombinationen).

Suisse - allemand - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - glukose - infusionslösung - glucosum 50 g ut glucosum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. corresp. 837 kj. - kalorien- und wasserzufuhr - synthetika

Suisse - allemand - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - glukose - infusionslösung - glucosum 100 g ut glucosum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. corresp. 1670 kj. - kalorien- und wasserzufuhr - synthetika

Suisse - allemand - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - glukose - infusionslösung - glucosum 200 g ut glucosum monohydricum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. corresp. 3350 kj. - kalorien- und wasserzufuhr - synthetika

Suisse - allemand - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - glukose - infusionslösung - glucosum 400 g ut glucosum monohydricum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. corresp. 6700 kj. - kalorien- und wasserzufuhr - synthetika